)

PepGen (PEPG) investor relations material
PepGen Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Discontinued PGN-EDO51 for Duchenne muscular dystrophy after failing to achieve target dystrophin levels; all DMD-related R&D activities wound down.
Focus shifted to PGN-EDODM1 for myotonic dystrophy type 1, with ongoing Phase 1 and Phase 2 trials and positive initial safety and splicing correction data.
Completed dosing in the 15 mg/kg cohort of the FREEDOM Phase 1 trial for DM1; topline data expected early Q4 2025.
Transitioning clinical sites to the FREEDOM2 Phase 2 multiple ascending dose trial, with initial results from the 5 mg/kg cohort anticipated in Q1 2026.
Appointed a new Chief Technology Officer in May 2025, bringing extensive experience in product and process development.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $74.7 million as of June 30, 2025, expected to fund operations into Q2 2026.
Net loss for the six months ended June 30, 2025, was $53.3 million; Q2 2025 net loss was $23.1 million ($0.70 per share), down from $28.3 million in Q2 2024.
Research and development expenses were $43.8 million for the first half of 2025, with Q2 2025 R&D at $18.4 million, down from $25.1 million year-over-year.
General and administrative expenses were $11.5 million for the first half of 2025, with Q2 2025 at $5.5 million, nearly flat year-over-year.
No revenue generated from product sales to date; all funding from equity offerings and financings.
Outlook and guidance
Existing cash and equivalents expected to fund operations into Q2 2026; additional capital will be required to continue operations beyond that point.
Topline data from the 15 mg/kg cohort of the FREEDOM trial expected in early Q4 2025; initial results from the 5 mg/kg cohort of the FREEDOM2 trial anticipated in Q1 2026.
Focused on advancing PGN-EDODM1 through ongoing and planned clinical trials, with key data readouts expected in late 2025 and early 2026.
Expenses and operating losses expected to continue as clinical and preclinical programs progress.
Next PepGen earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage